Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Tumor 2Breast Neoplasms 2Solid Tumors 1Oncologic Diseases 1Non-Small Cell Lung Cancer NSCLC 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Leukemia, Plasma Cell 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

tislelizumab 2pembrolizumab 2fludarabine phosphate 2fludarabine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2sintilimab 1pegfilgrastim 1liposomal doxorubicin 1Vinorelbine 1Vinblastine 1Specimen Handling 1Radiotherapy 1Proton Therapy 1Neuropsychological Tests 1Gemcitabine 1Fluorodeoxyglucose F18 1Doxorubicin 1Dacarbazine 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Hodgkin Disease × Fluorodeoxyglucose F18 × Clear all
NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
38 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡